Compare BridgeBio Pharma Inc (BBIO) vs Kohl's Corporation (KSS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Kohl's Corporation — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Kohl's Corporation trades at $18.49 (market cap $2.16B). The key difference: BridgeBio Pharma Inc is far larger — about 7.7× Kohl's Corporation's market cap, and Kohl's Corporation pays a 2.63% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | KSS | |
|---|---|---|
Market Cap | $16.61B | $2.16B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $24.71 |
52-Week Low | $47.29 | $11.72 |
Enterprise Value | $18.16B | $8.26B |
Dividend Yield | — | 2.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Kohl's (KSS) trades at $19.30, up 4.54% in the last session, with a bullish technical signal from moving averages. The stock shows attractive valuation ratios, including a P/E of 8.11 and P/B of 0.54, but faces revenue declines from $16.22B in 2025 to an expected $15.5B in 2026. Recent Q1 2026 earnings beat estimates, and the company appointed a new COO to drive operational improvements.
The outlook is mixed: low valuations and earnings beats offer upside, but persistent sales drops and thin net margins near 1.77% pose risks. Analyst consensus is cautious with a $16.75 price target below the current price, reflecting concerns over competitive pressures and cash flow volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →
